Journal ArticleDOI
The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model.
TLDR
The health economics of PRT could be an important consideration in decision making for this technology because of the potential broad‐spectrum risk reduction capability ofPRT.About:
This article is published in Transfusion.The article was published on 2010-11-01. It has received 73 citations till now. The article focuses on the topics: Cost effectiveness.read more
Citations
More filters
Journal ArticleDOI
Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.
TL;DR: This review gives an overview of the Mirasol PRT System, summarizing the mechanism of action, toxicology profile, pathogen reduction performance and clinical efficacy of the process.
Journal ArticleDOI
Transmission of west nile virus through blood transfusion in the United States in 2002
Journal ArticleDOI
Transfusion‐associated infections: 50 years of relentless challenges and remarkable progress
TL;DR: This review will address the response of the blood banking community to the major transfusion-transmitted infectious diseases (TTIDs) over the past 50 years, during which time the evolving appreciation of risk and progress in addressing TTIDs has been documented by more than 1000 publications in TRANSFUSION.
Journal ArticleDOI
Component pathogen inactivation: a critical review
TL;DR: This review summarizes the clinical evidence available for licensed component PI technologies and red cell PI under development and concludes that pathogen inactivation‐treated plasma and platelets are increasingly becoming the products of choice, where licensed.
Journal ArticleDOI
Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands.
TL;DR: The importance of characterizing standard transfusion products with current and emerging approaches (OMICS) and clinical outcome, and integrating this information on a database, thinking on the benefits it might bring in the future toward personalized transfusion therapies is highlighted.
References
More filters
Journal ArticleDOI
Recommendations of the Panel on Cost-effectiveness in Health and Medicine.
TL;DR: The basis for recommendations constituting the reference case analysis, the set of practices developed to guide CEAs that inform societal resource allocation decisions, and the content of these recommendations are described.
Journal ArticleDOI
Recommendations for Reporting Cost-effectiveness Analyses
TL;DR: Recommendations for the reporting of cost-effective analyses intended to improve the quality and accessibility of CEA reports are proposed to enhance the transparency of study methods, assist analysts in providing complete information, and facilitate the presentation of comparable cost-effectiveness results across studies.
Journal ArticleDOI
Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine.
TL;DR: Recommendations for the reporting of cost-effective analyses intended to improve the quality and accessibility of CEA reports are proposed to enhance the transparency of study methods, assist analysts in providing complete information, and facilitate the presentation of comparable cost-effectiveness results across studies.
Journal ArticleDOI
Transfusion-related immunomodulation (TRIM): An update
TL;DR: This review categorizes the available randomized controlled trials based on the inference(s) that they permit about possible mediators of TRIM, and examines the strength of the evidence available for relying on WBC reduction or autologous transfusion to prevent TRIM effects.
Journal ArticleDOI
Transmission of West Nile virus through blood transfusion in the United States in 2002.
Lisa N. Pealer,Anthony A. Marfin,Lyle R. Petersen,Robert S. Lanciotti,Peter L Page,Susan L. Stramer,Mary Grace Stobierski,Kimberly Signs,Bruce Newman,Hema Kapoor,Jesse L. Goodman,Mary E. Chamberland +11 more
TL;DR: Screening of potential donors with the use of nucleic acid-based assays for West Nile virus may reduce this risk of acquisition of the virus through transfused red cells, platelets, and fresh-frozen plasma.
Related Papers (5)
Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.
Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation : the SPRINT trial
Jeffrey McCullough,David H. Vesole,Richard J. Benjamin,Sherrill J. Slichter,Alvaro A. Pineda,Edward A. Snyder,Edward A. Stadtmauer,Ileana Lopez-Plaza,Steven Coutre,Ronald G. Strauss,Lawrence T. Goodnough,Joy Fridey,Thomas J. Raife,Ritchard G. Cable,Scott Murphy,Frank Howard,Kathryn B. Davis,Jin Sying Lin,Peyton S. Metzel,Laurence Corash,Antonis Koutsoukos,Lily Lin,Donald H. Buchholz,Maureen G. Conlan +23 more
Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial
Dick J. van Rhenen,Hans Gulliksson,Jean-Pierre Cazenave,Derwood Pamphilon,Per Ljungman,Harald Klüter,Hans Vermeij,M. C. Kappers-Klunne,Georgine E. de Greef,M. Laforet,Bruno Lioure,Kathryn B. Davis,Stephane Marblie,Veronique Mayaudon,Jocelyne Flament,Maureen G. Conlan,Lily Lin,Peyton S. Metzel,Don Buchholz,Laurence Corash +19 more
A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology
J. P. Cazenave,G Folléa,L. Bardiaux,Jean-Michel Boiron,B. Lafeuillade,M. Debost,Bruno Lioure,J‐L. Harousseau,Reza Tabrizi,Jean-Yves Cahn,Mauricette Michallet,Daniel R. Ambruso,R. Schots,Jean-Daniel Tissot,Luc Sensebe,T. Kondo,Jeffrey McCullough,Paolo Rebulla,Gines Escolar,P. Mintz,Nancy M. Heddle,Raymond P. Goodrich,J. Bruhwyler,C. Le,Richard J. Cook,B. Stouch +25 more